A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

Vaccine

Volumn 17, Issue 5, 1999, Pages 466-472

  Momeni, Ali Z ^a   Jalayer, Tahmores ^a   Emamjomeh, Morteza ^a   Khamesipour, Ali ^b   Zicker, Fabio ^c   Ghassemi, Reza Labaf ^a   Dowlati, Yahya ^b   Sharifi, Iraj ^d   Aminjavaheri, Mali ^a   Shafiei, Ali ^a   Alimohammadian, Mohammad Hossein ^e   Hashemi Fesharki, Reza ^f   Nasseri, Kiumarss ^g   Godal, Tore ^c   Smith, Peter G ^h   Modabber, Farrokh ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e PASTEUR INSTITUTE OF IRAN   (Iran)

^f Razi Institute   (Iran)

^g PUBLIC HEALTH INSTITUTE   (United States)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Clinical trial; Iran; Leishmaniasis; Vaccine

Indexed keywords

BCG VACCINE; LEISHMANIA MAJOR VACCINE; PAROMOMYCIN; PROTOZOAL VACCINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; IRAN; LEISHMANIA MAJOR; LYMPHADENOPATHY; MALE; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; PROMASTIGOTE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; SKIN TEST; VACCINATION; ZOONOSIS;

ADOLESCENT; ADULT; AGED; ANIMALS; BCG VACCINE; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; PROTOZOAN VACCINES; VACCINATION;

EID: 0033524709     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00220-5     Document Type: Article

References (20)

1. Desjeux P. Cutaneous leishmaniasis: clinical aspects. In Dowlati Y, Modabber F, editors. Clinics in dermatology, vol. 14. Amsterdam: Elsevier Science B.V., 1996. p. 417-423.
2. WHO Technical Report Series, No. 793, 1990.
3. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, WHO. Geneva: Progress Report 1995-1996. p. 100-111.
4. Nadim A., Javadian E. Leishmanization in the Islamic Republic of Iran. In: Walton B.C., Wijeyaratna P.M., Modabber F., editors. Research on control strategies for leishmaniasis, 1988. p. 336-339.
5. Green M.S., Kark J.D., Witztum E., Greenblatt C.L., Spira D.T. Frozen stored L. tropica vaccine: the effect of dose, route for administration and storage on the evolution of clinical lesion. Two field trials in the Israel defense forces. Trans R Soc Trop Med Hyg. 77:1983;152-159.
6. Convit J., Castellanos P.L., Rondon A., Pinardi M.E., Ulrich M., Castes M., Bloom B., Garcia L. Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis. Lancet. 1:1987;401-405.
7. Convit J., Castellanos P.L., Ulrich M., Castes M., Rondon A., Pinardi M.E., Rodrigues N., Bloom B., Formiga S., Valecillos L. Immunotherapy of localized, intermediate and diffuse forms of American cutaneous leishmaniasis. J Infect Dis. 160:1989;104-115.
8. Mayrink W., da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., Lima A.O., Michalick M.S., William P. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg. 73:1979;385-387.
9. Antunes C.M.F., Mayrink W., Magalhaes P.A., Costa C.A., Melo M.N., Dias M., Michalick M.S., William P., Lima A.O., Vieira J.B. Controlled field trials of a vaccine against new world cutaneous leishmaniasis. Int J Epidemiol. 15:1986;572-580.
10. Mohebali M., Javadian E.H., Hashemi-Fesharki R., Mohammadzadeh M., Nadim A., Tahvildar-Bidruni Gh., Mesdaghinia A Trial of a non-living crude vaccine against zoonotic cutaneous leishmaniasis. Med J Islamic Rep Iran. 8:1995;211-215.
11. Bahar K., Dowlati Y., Shidani B., Alimohammadian M.H., Khamesipour A., Ehsasi S., Hashemi-Fesharki R., Ale-Agha S., Modabber F. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. In: Dowlati Y., Modabber F., editors. Clinics in dermatology, vol. 14. Amsterdam: Elsevier Science B.V., 1996. p. 489-495.
12. Sharifi I., Fekri A.R., Aflatonian M.-R., Khamesipour A., Nadim A., Mousavi M.-R.A., Momeni A.Z., Dowlati Y., Godal T., Zicker F., Smith P.G., Modabber F. Double-blind randomised controlled vaccine trial of a single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam. Lancet. 351:1998;1540-1543.
13. Hashemi-Fesharki R., Alle-Agha S., Ahourai P., Djavadian E., Taghavi A., Golabi A., Kamali M., Esmail-Nia K., Ghafari H., Mofasali F., Kheirol-Omour R. Vaccine preparation and quality control of killed Leishmania major. Arch Inst Razi. 43:1992;39-50.
14. Sokal J.E. Measurement of delayed skin-test responses. N Eng J Med. 293:1975;501-502.
15. Castes M., Blackwell J., Trujillo D., Formica S., Cabrera M., Zorrilla G., Rondon A., Castellanos P.L., Convit J. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I. Skin-test reactivity T-cell proliferation and interferon-gamma production. Vaccine. 12:1994;1041-1051.
16. Smrkovski L.L., Larson C.L. Antigenic cross-reactivity between Mycobacterium bovis (BCG) and Leishmania donovani. Infect Immun. 18:1977;561-562.
17. Weintraub J., Weinbaum F.I. The effect of BCG on experimental cutaneous leishmaniasis in mice. J Immunol. 118:1977;2288-2290.
18. Stefani M.M., Muller I., Louis J. Leishmania major in BALB/C mice: protection or exacerbation by treatment with different doses of BCG. Res Immunol. 144:1993;233-243.
19. Sharples C.E., Shaw M.A., Castes M., Convit J., Blackwell J.M. Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: antibody responses to mycobacterial and leishmanial antigens. Vaccine. 12:1994;1402-1412.
20. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis. 177:1998;1352-1357.